{"id":"W2949252282","doi":"10.1136/annrheumdis-2019-eular.4166","title":"AB0738 DUAL NEUTRALISATION OF INTERLEUKIN (IL)–17A AND IL–17F WITH BIMEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 60-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLINDED, PHASE 2B EXTENSION STUDY","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Placebo; Ankylosing spondylitis; Internal medicine; Immune system; Dithranol; Interleukin 17; Psoriasis Area and Severity Index; Arthritis; Interleukin; Gastroenterology; Inflammation; Dermatology; Immunology; Pathology; Cytokine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002555584,0.002014182,0.003903666,0.0006189077,0.0004519881,0.001143823,0.001233643,0.001953198,0.005809887],"category_scores_gemma":[0.001214306,0.001120113,0.002174284,0.0004189454,0.001501845,0.001352996,0.0004740669,0.003658828,0.001530215],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005800823,"about_ca_system_score_gemma":0.001119834,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008502642,"about_ca_topic_score_gemma":0.001179152,"domain_scores_codex":[0.9992406,0.0003389716,0.00004640177,0.0001105128,0.0000801594,0.0001833212],"domain_scores_gemma":[0.9991452,0.0002132044,0.000124053,0.0000941405,0.00005632569,0.0003670218],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9375743,0.02073091,0.0004337284,0.0005714349,0.0007455013,0.00004735688,0.00009078505,0.0003960041,0.01211781,0.00009799995,0.0009209057,0.02627325],"study_design_scores_gemma":[0.8742888,0.1221373,0.001619241,0.0000205083,0.0002657485,0.00004548944,0.00002202442,0.000262789,0.0008096848,0.0000923979,0.00041865,0.00001733511],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931489,0.002935332,0.0005728223,0.0002998211,0.0003371328,0.001217981,0.0005140905,0.0001372515,0.000836534],"genre_scores_gemma":[0.9873607,0.002850538,0.00170807,0.0007502669,0.0005158162,0.002434116,0.000988896,0.00005719332,0.003334462],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005809887,"threshold_uncertainty_score":0.01943594,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05462284286593391,"score_gpt":0.2949990503727244,"score_spread":0.2403762075067905,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}